Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis: A Randomized, Double-blind, Placebo-controlled Study

NCT07143864 is registered in ClinicalTrials.gov with First Affiliated Hospital of Chongqing Medical University as lead sponsor.

NCT NCT07143864
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07143864 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis: A Randomized, Double-blind, Placebo-controlled Study
Lead sponsor
First Affiliated Hospital of Chongqing Medical University
Phase
Not applicable
Overall status
Not yet recruiting
Start date
September 15, 2025
Completion date
December 31, 2026
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

primary cutaneous amyloidosis